Anti-ANT3/ ATIII/ SERPINC1 monoclonal antibody

Anti-ANT3/ ATIII/ SERPINC1 antibody for FACS & in-vivo assay

Go to ATIII/SERPINC1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

SDSCOADatasheet
Inquiry

Product information

Size： 1mg | 10mg | 100mg

Product Description

Reference

Data / case study

Click to get more Data / Case study about the product.

Associated products

Target information

The target: ATIII, gene name: SERPINC1, also named as AT3, AT3D, ATIII, ATIII-R2, THPH7. The protein encoded by this gene, antithrombin III, is a plasma protease inhibitor and a member of the serpin superfamily. This protein inhibits thrombin as well as other activated serine proteases of the coagulation system, and it regulates the blood coagulation cascade. The protein includes two functional domains: the heparin binding-domain at the N-terminus of the mature protein, and the reactive site domain at the C-terminus. The inhibitory activity is enhanced by the presence of heparin. Numerous mutations have been identified for this gene, many of which are known to cause antithrombin-III deficiency which constitutes a strong risk factor for thrombosis. A reduction in the serum level of this protein is associated with severe cases of Coronavirus Disease 19 (COVID-19). [provided by RefSeq, Sep 2020].

About Gmab

GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s TaurusTM and LIBRATM platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.